TG Therap Rg
TGTX
USD
STOCK MARKET:
NMS
Closed
 
...
Large gap with delayed quotes
Last quote
08/15/2026 - 02:00:00
Bid
08/14/2026 - 21:59:59
Bid
Volume
Ask
08/14/2026 - 21:59:59
Ask
Volume
48.74
+0.80 ( +1.67% )
48.75
100
48.79
1,600
More information
Analysis by TheScreener
14.08.2026
Evaluation Neutral  
Interest Very weak  
Sensibility Middle  
Analysis date: 14.08.2026
Global Evaluation
  Neutral
The stock is classified in the neutral zone since 04.08.2026.
Interest
  Very weak
One star since 07.08.2026.
Earnings Rev Trend
  Negative
 
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 07.08.2026 at a price of 49.76.
Evaluation
  Undervalued
 
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
  Negative
 
The dividend-adjusted forty day technical trend is negative since 04.08.2026.
4wk Rel Perf
  -14.42%
 
The four-week dividend-adjusted underperformance versus SP500 is 14.42%.
Sensibility
  Middle
The stock has been on the moderate-sensitivity level since 04.08.2026.
Bear Market Factor
  Low
On average, the stock has a tendency to minimize the drops in the index by -0.87%.
Bad News Factor
  Low
When the stock's pressure is specific, the market sanction on average is 3.48%.
Mkt Cap in $bn
  7.46
With a market capitalization between $2 & $8bn, TG THERAPEUTICS is considered a mid-cap stock.
G/PE Ratio
  1.77
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
  13.02
The estimated PE is for the year 2028.
LT Growth
  23.00%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
  7
Over the last seven weeks, an average of 7 analysts provided earnings per share estimates.
Dividend Yield
  0.00%
The company is not paying a dividend.
Beta
  51
For 1% of index variation, the stock varies on average by 0.51%.
Correlation
  0.12
Stock movements are totally independent of index variations.
Value at Risk
  11.70
The value at risk is estimated at USD 11.70. The risk is therefore 24.00%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
  09.02.2021